Presentation at Cowen Healthcare Conference

RNS Number : 2637Q

Redx Pharma plc

25 February 2021

 

REDX PHARMA PLC

("Redx" or "the Company" or "Redx Pharma")

Redx Pharma to present at the Cowen 41^st Annual Health Care Conference

Alderley Park, 25 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that Lisa Anson, Chief Executive Officer, will give an update on progress made by the Company, at the Cowen 41st Annual Health Care Conference on Thursday 4 March, 2021 at 16:10 GMT / 11:10 EST.

A live webcast of the presentation will be available for viewing at:   https://wsw.com/webcast/cowen81/redx.l/2192577

Following the event, a recording will be made available on the investor section of the Company's website at:   https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/ .

For further information, please contact:
Redx Pharma Plc	T: [phone]
Iain Ross, Chairman Lisa Anson, Chief Executive Officer James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)	T: [phone]
Matt Davis/Adam Dawes
WG Partners LLP (Broker)	T: [phone]
Claes Spång/Chris Lee/David Wilson
FTI Consulting	T: [phone]
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical Proof of Concept. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

 

END

 

 

MSCEANALAEKFEFA